证券代码：603896 证券简称：寿仙谷 公告编号：2025-028 关于实际控制人及其一致行动人权益变动 债券代码：113660 债券简称：寿 22 转债 触及1%刻度暨增持计划进展的公告 浙江寿仙谷医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次权益变动属于同日披露的增持股份计划，不触及要约收购，不会导 致公司控股股东以及实际控制人发生变化。 本次权益变动情况：浙江寿仙谷医药股份有限公司（以下简称"寿仙谷" 或"公司"）实际控制人之一、董事兼总经理李振宇先生于 2025 年 4 月 30 日通 过上海证券交易所集中竞价方式增持公司股份 451,100 股，占公司总股本的 0.23%，增持金额为 8,792,137 元。本次权益变动后，李振宇先生及其一致行动人 合计持有公司股份数量由 76,867,050 股增加至 77,318,150 股，占公司总股本的比 例由 38.77%增加至 39.00%，股东权益变动触及 1%刻度线的整数倍。 本次增持计划尚未实施完毕，李振宇先生将继续按照本次 ...

浙江寿仙谷医药股份有限公司 关于实际控制人之一、董事兼总经理增持股份计划及 实施情况的公告 浙江寿仙谷医药股份有限公司（以下简称"寿仙谷"或"公司"）实际控 制人之一、董事兼总经理李振宇先生计划自 2025 年 4 月 30 日起 6 个月内，通过 上海证券交易所以集中竞价交易方式增持公司股份；本次增持不低于 2,000,000 股，不超过 3,964,877 股。 本次增持不设价格区间，将根据公司股票价格的二级市场波动情况，择 机实施增持计划。 公司收到通知，李振宇先生已于 2025 年 4 月 30 日通过集中竞价交易方 式买入公司股份 451,100 股，占公司总股本的 0.23%。 本次增持计划实施可能存在因市场发生变化或增持股份所需资金未能及 时到位等因素，导致增持计划延迟实施或无法达到预期的风险。增持计划实施过 程中如出现上述风险情形，公司将及时履行信息披露义务。敬请广大投资者注意 相关风险。 证券代码：603896 证券简称：寿仙谷 公告编号：2025-027 债券代码：113660 债券简称：寿 22 转债 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对 ...

| | | 浙江寿仙谷医药股份有限公司 关于举办 2025 年投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为更好与投资者沟通交流，便于广大投资者全面深入地了解浙江寿仙谷医药 股份有限公司（以下简称"公司"或"寿仙谷"）情况，公司拟举办 2025 年投资 者接待日活动，现将有关事项公告如下： 1、接待时间：2025 年 5 月 14 日 8:50-17:00 2、接待地点：公司基地—寿仙谷有机国药养生园；公司总部—浙江省武义 县黄龙三路 12 号。 3、公司主要参与人员：董事长李明焱、副董事长李振皓、董事兼总经理李 振宇、董事兼副总经理林荣志、董事兼副总经理徐靖、董事/副总经理兼董事会 秘书刘国芳、财务负责人祝彪、副总经理王汉波、投资者服务部总监曹秀娟（如 遇特殊情况，参会人员会有所调整） 电子邮箱：sxg@sxgoo.com 6、预约本次活动需签署《承诺书》（附件二），请投资者仔细阅读《承诺书》 条款并签署。 | 时间 | 活动内容 | 备注 | | --- | --- | --- | | 前 8: ...

Group 1 - The fifth China Shouxiangu Lingzhi Culture Festival was held in Hangzhou, showcasing the vibrant development of the Lingzhi industry through cultural markets, opening ceremonies, and Song Dynasty-themed banquets [1][3] - The festival creatively integrated traditional Chinese medicine culture with modern interactive experiences, allowing participants to appreciate the rich heritage of Lingzhi culture [3][5] - A highlight of the event was the Lingzhi Songyun Siya, featuring trendy products like Lingzhi coffee and various traditional entertainment projects, attracting many influencers [5] Group 2 - The "Songyun Elegant Banquet" included artistic performances that illustrated the legendary status of Lingzhi in traditional culture, emphasizing the cross-disciplinary appeal of "ancient recipes in modern cuisine" [5][7] - A panel discussion featured cross-industry guests discussing the modern relevance and influence of Lingzhi culture, highlighting its adaptability in contemporary life [7][9] - The festival launched the "Lingzhi Category Health Consumption White Paper," outlining standardized paths for the Lingzhi industry and proposing three major trends: technological advancement, youth engagement, and internationalization [9] Group 3 - The event focused on industry upgrades, with multiple organizations initiating the "Action Declaration for High-Quality Development of the Lingzhi Industry," emphasizing five key actions: technological innovation, quality supervision, industry-academia-research collaboration, market channel expansion, and cultural promotion [9] - A high-level academic exchange discussed the application prospects of wall-free Lingzhi spore powder in modern medicine, indicating a deep integration of traditional and modern medical practices [9] - The publication of "Shouxiangu Chronicles" documented the transformation of a century-old Chinese brand and the global journey of the Lingzhi industry [9]

公司代码：603896 公司简称：寿仙谷 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 Zhejiang Shouxiangu Pharmaceutical Co., Ltd. （浙江省武义县壶山街道商城路 10 号） 2024 年年度股东大会会议资料 二〇二五年五月十三日 浙江寿仙谷医药股份有限公司 2023 年年度股东大会会议资料 目 录 | 浙江寿仙谷医药股份有限公司 2024 年年度股东大会会议议程 1 | | --- | | 浙江寿仙谷医药股份有限公司 2024 年年度股东大会会议须知 3 | | 议案一：浙江寿仙谷医药股份有限公司董事会 2024 年度工作报告 5 | | 议案二：浙江寿仙谷医药股份有限公司监事会 年度工作报告 18 2024 | | 议案三：浙江寿仙谷医药股份有限公司 2024 年度财务决算报告 22 | | 议案四：浙江寿仙谷医药股份有限公司 2024 年度利润分配预案 28 | | 议案五：浙江寿仙谷医药股份有限公司 年年度报告（全文及摘要） 29 2024 | | 议案六：浙江寿仙谷医药股份有限公司 2025 年度日常关联交易预案 30 | ...

Core Viewpoint - The company experienced a significant decline in revenue and net profit in 2024, attributed to weak consumer demand, particularly affecting high-end products [1][2]. Financial Performance - In 2024, the company achieved revenue of 692 million yuan, a decrease of 11.81% year-on-year, and a net profit of 175 million yuan, down 31.34% from the previous year [1]. - For Q1 2025, revenue was 171 million yuan, a decline of 22.68% year-on-year, with a net profit of 58.37 million yuan, down 24.32% [1]. Product Category Analysis - High-end product sales, particularly Lingzhi spore powder, saw a more significant decline compared to mid- to low-end products. Lingzhi spore powder sales dropped by 16.46% to 446 million yuan in 2024 [2]. - Specific sales figures for Lingzhi spore powder products include: - Broken wall Lingzhi spore powder: 102 million yuan, down 20.23% - Broken wall Lingzhi spore powder: 221 million yuan, down 9.46% - Broken wall Lingzhi spore powder granules: 104 million yuan, down 24.46% - Broken wall Lingzhi spore powder slices: 18.63 million yuan, down 21.53% [2]. - Iron-clad Dendrobium products generated 113 million yuan in sales, a decrease of 11%, with specific declines in sales of Iron-clad Dendrobium granules and extracts [2]. Sales Volume and Pricing - The sales volume of Lingzhi spore powder products in 2024 was 25.72 tons, down 13.84%, with an average price of 17.33 yuan per gram, down 3.04% [3]. - Iron-clad Dendrobium products had a sales volume of 13.91 tons, up 7.33%, but the average price fell to 8.11 yuan per gram, down 17.08% [3]. Market Expansion and Strategy - The company reported that 65.23% of its revenue came from Zhejiang province, with only 9.61% from outside the province and 25.16% from online sales [3]. - Revenue growth rates for different regions showed declines: Zhejiang province down 7.52%, outside Zhejiang down 18.81%, and online sales down 19.51% [4]. - The company is restructuring its distributors and plans to enhance its presence in the provincial market through traditional and flagship store channels [4]. Competitive Advantage - The company has established a comprehensive supply chain model and developed proprietary technologies for its products, ensuring safety and efficacy [5]. - The company has cultivated 10 superior varieties of medicinal materials, including three types of Lingzhi and three types of Iron-clad Dendrobium [5]. - The unique low-temperature supersonic airflow breaking technology significantly enhances the absorption rates of active ingredients in its products compared to traditional methods [5]. Future Projections - Revenue projections for 2025-2027 are 732 million yuan, 815 million yuan, and 899 million yuan, representing year-on-year growth rates of 5.9%, 11.4%, and 10.2% respectively [6]. - Net profit forecasts for the same period are 191 million yuan, 219 million yuan, and 244 million yuan, with corresponding growth rates of 9.3%, 14.8%, and 11.4% [6].

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 1） 公司发布2024年报，营业收入6.92亿元，同比-11.81%；归母净利润1.75亿元，同比-31.34%；扣非归母净 利润1.43亿元，同比-36.96%；经营性净现金流2.13亿元，同比-32.25%；EPS（基本）0.88元。业绩符合市场预 期。 2） 公司发布2025年一季报，营业收入1.71亿元，同比-22.68%；归母净利润0.58亿元，同比-24.32%；扣非归 母净利润0.39亿元，同比-42.91%。业绩符合市场预期。 点评： 业绩短期承压，核心产品稳健支撑 2024Q1~2025Q1，公司单季度营业收入分别为2.21/1.32/1.19/2.20/1.71亿元，同比 +7.15%/-20.35 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's short-term performance is under pressure, but core products provide stable support. For the period from Q1 2024 to Q1 2025, the company's quarterly revenue figures are 221 million, 132 million, 119 million, 220 million, and 171 million yuan, showing a year-on-year change of +7.15%, -20.35%, -30.20%, -9.13%, and -22.68% respectively. The net profit attributable to the parent company for the same period is 77 million, 24 million, 18 million, 56 million, and 58 million yuan, with year-on-year changes of +23.19%, -14.05%, -63.77%, -51.32%, and -24.32% respectively. The poor performance is mainly attributed to changes in the macroeconomic environment and weak consumer demand [2][3] Summary by Relevant Sections Financial Performance - In 2024, the revenue from the company's core product categories shows a decline, with revenue from Ganoderma lucidum spore powder at 445 million yuan (65.75% of total revenue) down by 16.53% year-on-year, and revenue from Dendrobium candidum at 113 million yuan (16.63% of total revenue) down by 11.00% year-on-year. The sales model shows that the distribution model accounts for 58.57% (up 2.25 percentage points year-on-year), while direct sales (including online) account for 41.43%, with online sales at 171 million yuan (25.16% of total revenue) maintaining a stable layout [2] Marketing and International Expansion - The company is actively promoting marketing reforms and expanding its international presence. It continues to deepen the "famous doctors, famous medicines, famous stores" model, promoting the direct sales experience from Zhejiang to Shanghai and Jiangsu, and establishing a business pattern centered on Zhejiang with Shanghai and Jiangsu as wings. The company plans to add 10 specialty stores and strengthen cooperation with live streaming channels like Douyin and Li Jiaqi. In terms of internationalization, significant progress has been made in collaboration with the Mayo Clinic for research, advancing the commercialization of Ganoderma products in the U.S. and registering products in the EU [3] Profit Forecast and Valuation - The short-term recovery of consumer demand may impact the company's earnings elasticity. The net profit forecasts for 2025 and 2026 have been revised down to 192 million and 224 million yuan (originally forecasted at 355 million and 417 million yuan, both down by 46%). The newly added forecast for 2027 is a net profit of 251 million yuan, with year-on-year growth rates of 9.88%, 16.44%, and 12.23%. The current price corresponds to P/E ratios of 20, 17, and 15 times for 2025, 2026, and 2027 respectively. Given the company's product scarcity, technical standards barriers, and advantages in the entire industry chain, it has the ability to withstand cycles, and with policy support for traditional Chinese medicine, long-term growth is expected [3][4]

Investment Rating - The report maintains a rating of "Accumulate" for the company [5] Core Views - The company's short-term performance is under pressure, but core products provide stable support. The quarterly revenue from Q1 2024 to Q1 2025 shows fluctuations, with a peak of 2.21 billion yuan and a low of 1.19 billion yuan, reflecting a year-on-year change of +7.15% to -30.20%. The net profit also shows a decline, with a peak of 0.77 billion yuan and a low of 0.18 billion yuan, indicating a significant drop in profitability due to macroeconomic changes and weak consumer demand [2][3] - The company is advancing marketing reforms and expanding its international presence. It is implementing a "famous doctor, famous medicine, famous store" model and plans to enhance its presence in the Yangtze River Delta region. The internationalization efforts include collaboration with the Mayo Clinic and registration of products in the EU, which opens up overseas market opportunities [3][4] Financial Performance Summary - The company's revenue for 2024 is projected at 6.92 billion yuan, a decrease of 11.81% year-on-year, with a net profit of 1.75 billion yuan, down 31.34% [9] - The revenue for 2025 is estimated at 7.34 billion yuan, with a net profit of 1.92 billion yuan, reflecting a recovery trend with a growth rate of 9.88% in 2027 [4][10] - The earnings per share (EPS) for 2024 is expected to be 0.88 yuan, with a gradual increase to 1.27 yuan by 2027 [10][12] Profitability and Valuation Metrics - The company's gross margin is projected to be 80.7% in 2024, with a slight decline to 80.6% by 2027. The return on equity (ROE) is expected to improve from 7.6% in 2024 to 9.0% in 2027 [12][13] - The price-to-earnings (P/E) ratio is forecasted to be 22 in 2024, decreasing to 15 by 2027, indicating a more attractive valuation over time [12][13] Market Position and Strategy - The company is focusing on enhancing its sales channels, with a significant portion of revenue coming from e-commerce, which accounted for 25.16% of total sales in the latest quarter. The company plans to open 10 new specialty stores and strengthen partnerships with online influencers [2][3] - The geographical revenue distribution shows that 65.23% of income comes from Zhejiang province, with ongoing efforts to reform distributors in other provinces like Guangdong and Anhui [2][3]

精测电子：2024年净亏损9759.85万元 4月24日晚，精测电子（300567）发布2024年年度报告，公司2024年实现营业收入25.65亿元，同比增长 5.59%；实现归属于上市公司股东的净亏损9759.85万元，同比由盈转亏；基本每股收益为亏损0.35元/ 股。 神剑股份：2024年净利润同比增长32.29% 拟10派0.5元 4月24日晚，神剑股份（002361）发布2024年年度报告，公司2024年实现营业收入24.18亿元，同比下降 5.97%；实现归属于上市公司股东的净利润3365.07万元，同比增长32.29%；基本每股收益为0.0354元/ 股。公司拟向全体股东每10股派发现金红利0.5元（含税）。 资料显示，神剑股份成立于2002年4月，专业从事聚酯树脂系列产品的生产销售。 所属行业：基础化工–塑料–合成树脂 资料显示，精测电子成立于2006年4月，主营业务为显示、半导体、新能源检测系统的研发、生产与销 售。 所属行业：机械设备–通用设备–仪器仪表 经纬股份：2024年净利润同比下降36.76% 拟10派1元 4月24日晚，经纬股份（301390）发布2024年年度报告，公司2024年 ...